Skip to content
  • Sunday, 26 July 2026
  • 4:32 am
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Retatrutide eases sleep apnea and knee arthritis in new Phase 3 data, extending Lilly’s obesity lead over Novo
Laboratory Automation & Robotics

Retatrutide eases sleep apnea and knee arthritis in new Phase 3 data, extending Lilly’s obesity lead over Novo

Lana Keisha Jul 18, 2026 0

Eli Lilly and Company has announced groundbreaking Phase 3 results for its investigational triple agonist, retatrutide, demonstrating significant efficacy in…

Read More
Laboratory Automation & Robotics

Retatrutide eases sleep apnea and knee arthritis in new Phase 3 data, extending Lilly’s obesity lead over Novo

Lana Keisha Jul 11, 2026 0

Eli Lilly has significantly bolstered its position in the competitive metabolic disease landscape with detailed Phase 3 results for its…

Read More
Laboratory Automation & Robotics

Retatrutide eases sleep apnea and knee arthritis in new Phase 3 data, extending Lilly’s obesity lead over Novo

Lana Keisha Jul 1, 2026 0

Eli Lilly and Company utilized the prestigious platform of the American Diabetes Association’s (ADA) annual meeting to unveil groundbreaking Phase…

Read More
Laboratory Automation & Robotics

Retatrutide eases sleep apnea and knee arthritis in new Phase 3 data, extending Lilly’s obesity lead over Novo

Lana Keisha Jun 22, 2026 0

The Dawn of a New Era in Metabolic Disease Management The announcement at the ADA meeting highlighted retatrutide’s remarkable efficacy,…

Read More
Laboratory Automation & Robotics

Retatrutide Eases Sleep Apnea and Knee Arthritis in New Phase 3 Data, Extending Lilly’s Obesity Lead Over Novo

Lana Keisha Jun 15, 2026 0

Eli Lilly announced groundbreaking detailed Phase 3 results for its investigational triple agonist, retatrutide, at the American Diabetes Association’s (ADA)…

Read More
Pharmaceutical R&D

Gilead Sciences Pledges Over 400,000 Doses of AmBisome to Combat Visceral Leishmaniasis, Extending Vital Global Health Partnership

Teuku Ryan May 21, 2026 0

Gilead Sciences has announced a significant commitment to global health, pledging over 400,000 doses of its vital antifungal medication, AmBisome…

Read More
Molecular & Cell Biology

Naked Mole Rat Gene Transfer to Mice Offers Glimpse into Extending Mammalian Healthspan

Angie Faith May 10, 2026 0

In a groundbreaking development that blurs the lines between species and aging research, scientists have successfully transferred a key longevity-associated…

Read More
Environmental & Analytical Chemistry

A Blood Filter Shows Promise in Extending Pregnancies Affected by Preeclampsia

Abdurrohim Arsyad May 5, 2026 0

A groundbreaking, albeit small-scale, clinical trial has offered a glimmer of hope for pregnant individuals battling preeclampsia, a serious and…

Read More
Biotech & Genetic Research

The biotech bi-weekly: genome editing, life-extending therapeutics, an early-stage biotech hub and more

Jia Lissa Mar 18, 2026 0

The biopharmaceutical and biotechnology sectors have recently experienced an extraordinary period of accelerated activity, marked by a rapid succession of…

Read More
TWiV 1284: Clinical Update with Dr. Daniel GriffinPfizer and Astellas Secure FDA Priority Review for Perioperative Padcev and Keytruda Combination in Muscle-Invasive Bladder CancerTWiV 1291: A foot in the door for cytomegalovirusLudwig Cancer Research Study Identifies Novel Combination Therapy to Overcome Differentiation Blockade in Acute Myelogenous Leukemia
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must HaveJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’sKing’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid DecompositionSanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Lana Keisha Jul 25, 2026
Neuroscience & Brain Research
King’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286
Rifan Muazin Jul 25, 2026
Advanced Materials Science
Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid Decomposition
Nila Kartika Wati Jul 25, 2026
Pharmaceutical R&D
Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
Teuku Ryan Jul 25, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ